Objective To develop an UPLC-MS/MS to determine the concentration of licochalcone A in the plasma of Beagle dogs and the pharmacokinetics after a single dose intravenous and oral administration of licochalcone A,respectively.Methods Beagle dogs were intravenously and orally administered licochalcone A(3 mg·kg-1).The plasma samples were collected at different time spots.UPLC-MS/MS was used to determine the concentration of licochalcone A in the plasma.The plasma concentration-time curves were fit by DAS 2.1.1 software to determine the pharmacokinetic parameters of licochalcone A.Results The linear regression of licochalcone A in the plasma was:Y=0.039X+0.1959,R2=0.9997,and the linear range was 2～2000 μg·L-1.In the intravenous administration model,the half-life(t1/2)of licochalcone A in the plasma was 6.57 h,the area under the drug-time curve(AUC0～t)was 1665 h·mg·L-1,the mean residence time(MRT0～t)was 5.68 h,and the clearance rate(CL)was 2106 L·h-1·kg 1.While in the oral administration model,the t1/2 of licochalcone A in the plasma was 8.23 h,AUC0～t was 397 h·mg·L-1,the MRT0～t was 9.35 h,and the oral bioavailability was 23.8％.Conclusion The UPLC-MS/MS method is accurate and applicable for the pharmacokinetic study of licochalcone A in the plasma of Beagle dogs.Licochalcone A shows moderate oral bioavailability.
NETL
NSTL
万方数据
